title: Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs.
abstract: The effect of ranitidine in preventing mucosal damage caused by nonsteroidal antiinflammatory drugs (NSAIDs) was evaluated for eight weeks in a prospective study of 144 patients requiring NSAIDs. Patients with normal endoscopic findings were randomly assigned to receive either ranitidine 150 mg twice daily or placebo for eight weeks, along with either ibuprofen, indomethacin, naproxen, sulindac, or piroxicam. Duodenal damage was significantly less in the ranitidine group compared with the placebo group by weeks 4 and 8 (P less than or equal to 0.01). Duodenal ulcers did not develop in any patients on ranitidine (0/57) compared with 4/49 patients (8%) on placebo (P = 0.02). No significant difference was found between treatment groups with respect to gastric damage; 6/60 (10%) in the ranitidine group compared with 6/50 (12%) in the placebo group developed gastric ulcers. These findings suggest that acid suppression is of greater importance for mucosal protection in the duodenum than in the stomach, where other defense mechanisms may be operative. While ranitidine is an effective prophylaxis for NSAID-induced damage in the duodenum, further studies are needed to define specific risk groups and to assess the potential usefulness of more complete acid suppression in preventing gastric mucosal damage.
authors.affiliation: Department of Medicine, University of Oklahoma, Oklahoma City.
authors.forename: M G
authors.initials: MG
authors.lastname: Robinson
authors.forename: J W
authors.initials: JW
authors.lastname: Griffin
authors.forename: J
authors.initials: J
authors.lastname: Bowers
authors.forename: F J
authors.initials: FJ
authors.lastname: Kogan
authors.forename: D G
authors.initials: DG
authors.lastname: Kogut
authors.forename: F L
authors.initials: FL
authors.lastname: Lanza
authors.forename: C W
authors.initials: CW
authors.lastname: Warner
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000517:prevention & control; D004386:Duodenum / Q000187:drug effects / Q000473:pathology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011446:Prospective Studies; D011897:Random Allocation; D011899:Ranitidine / Q000627:therapeutic use*; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011899:Ranitidine